Latest Contribution
Two-year GATHER2 data: anatomical gains, functional questions for avacincaptad pegol in geographic atrophy
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) remains a leading cause of irreversible central vision loss, and complement dysregulation has long been implicated in its pathogenesis. In 2023, the US FDA approved the first two GA therapies, both...
ROCK inhibition after descemetorhexis without endothelial keratoplasty: a small but timely Indian RCT
The authors present a single-centre, prospective, randomised, comparative clinical trial (RCT) of 24 eyes of 24 patients with mild-to-moderate Fuchs endothelial corneal dystrophy (FECD) undergoing combined phacoemulsification and a standardised 4mm central descemetorhexis without endothelial keratoplasty (DWEK), with or without...
Aspiration of anteriorly migrated dexamethasone implant using an 18G intravenous cannula
Intravitreal dexamethasone (Ozurdex 0.7mg) is a biodegradable, sustained-release implant used to manage diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and non-infectious posterior uveitis due to its anti-inflammatory effects and VEGF suppression [1]. While effective, the implant may...
